Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Austria / NCT05339178
Recruiting Observational

Quality of Life of Periodontitis Patients Visiting Supportive Periodontal Therapy

NCT05339178 · tracked via the Priya Life Science Austria tracker
Sponsor
Medical University of Vienna
Phase
Observational
Started
2022-01-10
Last updated
2022-04-21

Condition(s) studied

Quality of LifePeriodontal Diseases

Study summary

The present prospective study aims to assess the QoL of periodontitis patients during supportive treatment and to relate it to periodontal health (clinical and radiographic data) and treatment stability. Follow-ups after the first cross-sectional assessment are planned after approximately 2.5, 5, 7.5, and 10 years.

Eligibility

Sex
ALL
Min age
18 Years
Max age
130 Years
Healthy volunteers
No
Inclusion Criteria: * All patients returning for supportive therapy on a regular basis after active periodontal treatment will be asked for participation if they are in supportive therapy for at least 1 year.

Primary outcome measure(s)

  • disease specific OHRQoL (ParoQoL) — at baseline
  • disease specific OHRQoL (ParoQoL) — after 2.5 years
  • disease specific OHRQoL (ParoQoL) — after 5 years
  • disease specific OHRQoL (ParoQoL) — after 7.5 years
  • disease specific OHRQoL (ParoQoL) — after 10 years

Trial sites (1)

FacilityCityRegionStatus
Division of Oral Surgery, School of Dentistry, Medical University of Vienna Vienna Austria Recruiting

More Medical University of Vienna trials in Austria

Edge-to-edge Mitral Valve Repair in ATTR-CM Recruiting
Ketamine in OCD: Efficacy and Effects on Stress and Cognition Recruiting
Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients Recruiting
LETHE-AT: a Personalized Multidomain Lifestyle Intervention for Individuals at Increased Risk of Memory Impairment. Starting soon
A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients Recruiting

Other trials for the same condition

Effects of Ashwagandha Supplementation on Quality of Life and Well-Being in Women With Endometriosis Starting soon
International CIPN Assessment and Validation Study Recruiting
Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05339178 on ClinicalTrials.gov ↗ ← All trials in Austria